| Co-Investigator(Kenkyū-buntansha) |
TAMEI Hironori Fuji-Yakuhin Kogyo Co., Research Institute Research Member, 主任
IWATA Kazushi Fuji-Yakuhin Kogyo Co., Research Institute Research Head, 主席
HAYASHI Tatsuya Mie University School of Medicine, Assistant, 医学部, 助手 (00242959)
TAKEYA Hiroyuki Mie University School of Medicine, Assistant, 医学部, 助手 (60222105)
IDO Masaru Mie University School of Medicine, Lecturer, 医学部, 講師 (90167263)
|
|---|
| Research Abstract |
The blood fluidity in the vessel is maintained by the activation of several anticoagulant and fibrinolytic systems, such as anticoagulant protein C pathway system, antithrombin III-heparan sulfate system, and tissue plasminogen activator (t-PA) -plasminogen system, on the surface of normal vascular endothelial cells. However, when the endothelial cells are injured by some physical, chemical and/or biological stimulants, the ability to maintain the blood fluidity by anticoagulant and fibrinolytic systems on the endothelial cells are broken down, then, resulting in thromboembolic disease in specific or non-specific organs (multi-organs failure). Thus, to diagnose the signals of the injured endothelium as early as possible is critical to prevent the patients from the occurring of thrombotic disease. The present study was aimed to develop the assay kits for determining the molecular markers to detect the early stage of the endothelial injury and to apply the assay kits for several diseases having a tendency to fall in thrombotic disease. We developed ELISA kits to assay soluble thrombomodulin (sTM) , soluble E-selectin (sE-S) and activated protein C-protein C inhibitor complex (CIC) , and found that these assay kits are useful to get information of the injury of endothelium in the hereditary and acquired thrombotic diseases, such as hereditary deficiency of protein C or S,diabetes mellitus and autoimmune disease.
|
